公司資料
SELLAS Life Sciences Group, Inc. 股價、新聞與催化劑
- 股票代碼:
- SLS
- 交易所:
- NASDAQ
- 產業:
- Life Science Tools
- 所在地:
- United States
股票表現
13.00 USD (+1.72%)
收盤價
最後更新: 2026年8月17日
1.55B USD
市值
股價為何變動
As of Aug 17, 2026, SLS closed up 1.72% at $13.00. No new same-company headline was identified in the current news window.
公司概覽
Late-Stage Oncology Company
SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor.
Galinpepimut-S
Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer Center. WT1 is expressed across multiple blood cancers and solid tumors, creating potential for both monotherapy and combination development.
REGAL Phase 3 Program
The Phase 3 REGAL trial evaluates GPS as maintenance therapy in acute myeloid leukemia patients who achieved complete remission after second-line salvage treatment. The event-driven study will proceed to final analysis after the prespecified 80th event.
SLS009
SLS009, also known as tambiciclib, is a selective CDK9 inhibitor designed to combine antitumor potency with reduced toxicity. SELLAS is evaluating the candidate in newly diagnosed frontline AML and preparing for potential clinical development in pancreatic cancer.
未來催化劑
- The prespecified 80th event in the Phase 3 REGAL study, triggering database lock, final analysis, and subsequent topline results.
- Topline data from the Phase 2 study of SLS009 in newly diagnosed frontline AML in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。